EADV 2026 data highlight dupilumab’s effects on growth, quality of life, disease control, and itch across multiple dermatologic diseases.
|Articles|September 1, 2003
Not Doing the Job
Author(s)Beth Kapes
Barcelona - With a view on managing alopecia areata that is in complete contrast to the position commonly taken in the United States, Rudolf Happle, M.D., brings forward an interesting question: Why do dermatologists continue to use topical corticosteroids [and other treatments] if they are not truly effective in treating all forms of AA?
Advertisement
Advertisement
Related to this article
The FDA approval, based on 36-week data from the phase 3 BRAVE-AA-PEDS trial, extends baricitinib access to patients as young as 12 years old with severe alopecia areata.
The designation marks the first FDA Fast Track status granted to a therapy for peeling skin syndrome, which currently has no approved treatment.
New review explores why eczema and ADHD often overlap in youth, highlighting sleep loss, itch-driven inflammation, plus screening and treatment tips.
Advertisement
Advertisement
Trending on Dermatology Times
1
FDA Approves Baricitinib for Adolescents With Severe Alopecia Areata
2
Alopecia Areata Awareness Month: 2026 in Review
3
Tremfya Meets Primary, Major Secondary Endpoints in Phase 4 STAR Study of Axial PsA
4
Dermatology FDA and Pipeline Review: Q3 2026 Approvals and Readouts
5